Clinical Trial Update: Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC [Phase 2]

View source ↗

Summary

Phase 2 trial assessing restoration of I-131 uptake with selpercatinib in RET fusion-positive, radioiodine-refractory thyroid cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Carcinoma
• Papillary Thyroid Carcinoma
• Thyroid Cancer

Drugs mentioned

• Iodine-131 (Iodine-131)
• RETEVMO (selpercatinib)
• Selpercatinib (selpercatinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Thyroid Cancer, Thyroid Carcinoma | Phase 2 | Status: RECRUITING